Open AccessGenotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function
Author(s) -
Ulf Hindorf,
Malin Lindqvist Appell
Publication year - 2011
Publication title -
journal of crohn s and colitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.277
H-Index - 80
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1016/j.crohns.2011.11.014
Subject(s) - thiopurine methyltransferase , genotyping , concordance , genotype , adverse effect , genotype phenotype distinction , medicine , biology , genetics , pharmacology , azathioprine , gene , disease
A pre-treatment determination of the thiopurine S-methyltransferase (TPMT) genotype or phenotype can identify patients at risk of developing severe adverse reactions from thiopurine treatment. The risk of misclassifying a patient might be dependent on the method used. The aim of this study was to investigate the concordance between TPMT genotyping and phenotyping.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom